arrow
X

Xuyang Song

Ningxia Medical University
H指数:12
被引数:715

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance

tremelimumab在晚期实体瘤患者中的群体药代动力学模型以及疾病状态对时变清除率的影响

2022-12-256
PRE
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

加拿大癌症试验组IB期研究durvalumab (anti-PD-L1) 联合tremelimumab (anti-CTLA-4) 同时或顺序给予晚期,无法治愈的实体恶性肿瘤患者

2020-02-040
PREAI
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
2019-03-0171
PREAI